Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for MN-166 (ibudilast) in Neuropathy, Neurological disorder. The expected timing is based on the latest available company guidance and may change.
Plans to initiate a Phase 2b study were announced in October 2020 and currently is ongoing. No recent updates on timing (Q2 2023). 12/18/25:- OXTOX Ph2 CIPN trial enrollment completed; topline data in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.